ErbB antagonists patenting: "playing chess with cancer"

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) signaling pathways are crucial in solid tumor development.
• Dysregulated ErbB signaling drives cell cycle progression (MAPK pathway) and survival (PI3K pathway) in many cancers.

Purpose of the Study:

• To review the development and clinical application of ErbB antagonists, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs).
• To discuss the mechanisms of resistance encountered with current ErbB-targeted therapies.
• To highlight the emerging strategy of combination therapies for overcoming treatment resistance.

Main Methods:

• Review of patented monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) targeting ErbB receptors.
• Analysis of clinical applications and resistance mechanisms associated with approved anti-ErbB drugs.
• Exploration of future therapeutic strategies involving combination treatments.

Main Results:

• Approved mAbs (Trastuzumab, Cetuximab, Panitumumab) and TKIs (Gefitinib, Erlotinib, Lapatinib) target EGFR and/or HER2.
• Resistance to mAbs occurs via compensatory signaling, while TKI resistance arises from mutations in the tyrosine kinase domain.
• Drug resistance significantly limits the efficacy of current monotherapies.

Conclusions:

• Monoclonal antibodies and tyrosine kinase inhibitors targeting ErbB signaling are vital in cancer treatment.
• Mechanisms of resistance, including compensatory signaling and target mutations, pose significant challenges.
• Combination therapy represents a promising future strategy to overcome resistance and improve cancer treatment efficacy.